Owner Scorecard


← All companies ← CRM Manual CRNC → ← CPRX Pharmaceuticals CRNX →

CRMD, CorMedix Inc.

Pharmaceuticals consumer brand

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions.

According to the 2025 United States Renal Disease System, reporting data from 2023, there were approximately 485,000 End-Stage-Renal-Disease ("ESRD") patients on permanent hemodialysis in the U.S. and over 25% of these utilized a CVC for vascular access.

Latest annual: FY2025 10-K
CRMD · CorMedix Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$312M
+617.0% YoY · 306% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $462M 5-yr avg $71M
Operating margin 47.0% 5-yr avg −1.6%
ROIC 98% 5-yr avg −272%
Owner-earnings margin 54% 5-yr avg −30%
Free cash flow margin 54% 5-yr avg −11738%

Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~43 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is DefenCath (83%), Melinta Portfolio (15%) and Contract revenue (2%).
What moves the needle
The pipeline against the patent cliff, and pricing. What decides it: whether new drugs replace those losing exclusivity, the odds in the clinical pipeline, and how durable pricing stays against payers and generics. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −202%, above 15% in 1 of 8 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

DefenCath is 83% of revenue, with Melinta Portfolio the other meaningful line at 15%.

Revenue by product line, FY2025
  • DefenCath83%$259M
  • Melinta Portfolio15%$46M
  • Contract revenue2%$7M

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

Most recent quarterly filing 10-Q filed Aug 13, 2026 Source at SEC EDGAR →

Revenue up 156.5% year over year; operating income up 119.6%

figures computed from the filing's XBRL

The record, 2015–2025

realized figures from each filing · older years to the left
2015’152016’162017’172018’182019’192020’202021’212022’222024’242025’25TTMTTMJun 2026
Income statement
$210K$224K$329K$430K$283K$239K$191K$65K$43M$312M$462MRevenueRevenue
($109K)($143K)$214K$33K($90K)$34K$42K$62K$430MGross profitGross prof.
−52%−64%65%8%−32%14%22%94%93%Gross marginGross mgn
n/mn/mn/mn/mn/mn/mn/mn/m135%34%9%SG&A / revenueSG&A/rev
n/mn/mn/mn/mn/mn/mn/mn/m9%6%6%R&D / revenueR&D/rev
($17M)($25M)($33M)($27M)($21M)($27M)($29M)($31M)($22M)$150M$217MOperating incomeOp. inc.
n/mn/mn/mn/mn/mn/mn/mn/m−51.4%48.2%47.0%Operating marginOp. mgn
($18M)($25M)($33M)($27M)($21M)($27M)($29M)($30M)($19M)$150MPretax incomePretax
($18M)($25M)($33M)($27M)($16M)($22M)($28M)($30M)($18M)$163M$187MNet incomeNet inc.
Cash flow & returns
($13M)($22M)($29M)($24M)($15M)($22M)($21M)($24M)($51M)$175M$254MOperating cash flowOp. cash
$15K$26K$37K$74K$73K$128K$62K$85K$154K$677KDepreciationDeprec.
$2M$1M$3M$2M($1M)($3M)$2M$1M($39M)($3M)$50MWorking capital & otherWC & other
$15K$59K$152K$49K$37K$113K$1M$219K$116K$2M$4MCapexCapex
7.4%26.2%46.2%11.4%12.9%47.1%746.5%335.4%0.3%0.7%0.8%Capex / revenueCapex/rev
($13M)($22M)($29M)($24M)($15M)($22M)($21M)($24M)($51M)$174M$250MOwner earningsOwner earn.
n/mn/mn/mn/mn/mn/mn/mn/m−116.7%55.9%54.2%Owner earnings marginOE mgn
($13M)($22M)($29M)($24M)($15M)($22M)($23M)($25M)($51M)$173M$250MFree cash flowFCF
n/mn/mn/mn/mn/mn/mn/mn/m−116.7%55.4%54.2%Free cash flow marginFCF mgn
($24M)$11M$10M$2M($12M)$7M($9M)($4M)$21M($308M)Investing cash flowInv. cash
$44M$7M$21M$29M$26M$40M$42M$18M$26M$238MFinancing cash flowFin. cash
($17K)$245$20K($8K)($2K)$13K($13K)($9K)($2K)Exchange-rate effectFX
$7M($4M)$2M$7M($1M)$26M$11M($10M)($3M)$105MChange in cashΔ cash
-59%-201%-227%-928%-245%-203%-40%58%98%ROICROIC
-53%-138%-459%-544%-69%-50%-45%-54%-21%40%41%Return on equityROE
−53%−138%−459%−544%−69%−50%−45%−54%−21%40%41%Retained to equityRetained/eq
Balance sheet
$35M$20M$12M$18M$28M$46M$65M$59M$52M$149M$257MCash & investmentsCash+inv
$316K$12K$64K$11K$35$3K$45K$52M$171M$161MReceivablesReceiv.
$377K$167K$594K$429K$338K$144K$3K$8M$30M$39MInventoryInvent.
$2M$2M$2M$3M$1M$1M$2M$2M$2M$8M$10MAccounts payablePayables
($1M)($1M)($1M)($2M)($686K)($981K)($2M)$58M$193M$190MOperating working capitalOper. WC
$37M$22M$13M$19M$29M$48M$66M$60M$115M$367M$481MCurrent assetsCur. assets
$3M$4M$6M$8M$6M$4M$5M$6M$34M$174M$187MCurrent liabilitiesCur. liab.
12.1×5.3×2.1×2.4×5.0×11.6×12.4×9.4×3.4×2.1×2.6×Current ratioCurr. ratio
$38K$70K$186K$161K$122K$111K$1M$2M$2M$6MNet PP&ENet PP&E
$37M$22M$13M$19M$29M$49M$69M$62M$119M$826M$904MTotal assetsAssets
$0$6M$150K$150KTotal debtDebt
($12M)($11M)($148M)($257M)Net debt / (cash)Net debt
-4201.3×-18887.0×-5859.4×-14342.9×-26.7×-819.3×-1846.4×-1155.0×-621.0×54.0×78.0×Interest coverageInt. cov.
$3M$4M$6M$14M$6M$5M$6M$7M$34M$421MTotal liabilitiesTotal liab.
$34M$18M$7M$5M$24M$44M$63M$55M$85M$405M$461MShareholders’ equityEquity
n/m595.8%503.8%258.4%861.2%n/mn/mn/m14.1%4.4%3.5%Stock comp / revenueSBC/rev
Per share
31.3M38.0M55.1M17.8M24.2M28.6M37.7M40.3M58.9M80.3M92.5MShares out (diluted)Shares
$0.01$0.01$0.01$0.02$0.01$0.01$0.01$0.00$0.74$3.88$4.99Revenue / shareRev/sh
$-0.58$-0.65$-0.60$-1.51$-0.68$-0.77$-0.75$-0.74$-0.30$2.03$2.02EPS (diluted)EPS
$-0.40$-0.59$-0.52$-1.33$-0.62$-0.77$-0.56$-0.61$-0.86$2.17$2.71Owner earnings / shareOE/sh
$-0.40$-0.59$-0.52$-1.33$-0.62$-0.77$-0.60$-0.61$-0.86$2.15$2.71Free cash flow / shareFCF/sh
$0.00$0.00$0.00$0.00$0.00$0.00$0.04$0.01$0.00$0.03$0.04Cap. spending / shareCapex/sh
$1.09$0.47$0.13$0.28$0.98$1.55$1.67$1.37$1.44$5.05$4.98Book value / shareBVPS

The diluted share count moved ×1.45 into 2017 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1/3.09 into 2018 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.46 into 2024 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
10-yr5-yr
Revenue / share+88.9%/yr+241.3%/yr
Capital spending / share+49.9%/yr+48.1%/yr
Book value / share+16.6%/yr+26.7%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned $174M of owner earnings, the operating cash left after the $677K it takes just to hold its position. It put $2M more into growth; free cash flow, after that spending, was $173M.

Reported net income$163M
Owner earnings$174M · 56% of revenue
FY2025FY2024FY2022FY2021FY2020
Reported net income$163M($18M)($30M)($28M)($22M)
Depreciationnon-cash charge added back+$677K+$154K+$85K+$62K+$128K
Amortization of intangible assetsnon-cash charge added back; the purchase price of past acquisitions, expensed over time+$14M+$156K
Stock-based compensationreal costnon-cash, but a real cost+$14M+$6M+$4M+$5M+$2M
Working capital & othertiming of cash in and out, other non-cash items−$16M−$39M+$1M+$2M−$3M
Cash from operations$175M($51M)($24M)($21M)($22M)
Maintenance capital expenditurethe spending needed just to hold position and volume−$677K−$116K−$85K−$62K−$113K
Owner earnings$174M($51M)($24M)($21M)($22M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$2M−$135K−$1M
Free cash flow$173M($51M)($25M)($23M)($22M)
Owner-earnings marginowner earnings ÷ revenue56%-117%-37368%-11112%-9230%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $677K, roughly its depreciation, the rate its assets wear out). The other $2M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $14M), owner earnings is nearer $161M.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

Dashed amortization years: the filer did not tag the intangible-amortization line that year, so that year's charge remains inside "Working capital & other."

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Comfortable
    Operating income $150M ÷ interest expense $3M
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • Net cash
    Cash $145M + ST investments $4M − debt $6M
    What this means

    Cash and short-term investments exceed every dollar of debt by $142M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    8-yr median, range -928%–58%; 56% latest = NOPAT $150M ÷ invested capital $267M
    Industry peers: median -7%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 8 years (it ran 56% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High
    Owner earnings $174M = operating cash $175M − maintenance capex $677K
    Industry peers: median -1%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 56% of revenue this year. Treating stock comp as the real expense it is (less $14M of SBC) leaves $161M.

  • Cash-backed
    Cash from ops $175M ÷ net income $163M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 3.34×
    Expanding
    Capex $2M ÷ property depreciation $677K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Sells itself
    Selling and marketing $38M ÷ revenue $312M
    What this means

    Sales and marketing as a share of revenue, kept apart from administrative overhead because it answers a different question: how much a business must spend to win the next customer. A company whose product pulls customers in spends little here and keeps the difference; one that must buy its growth is running to stand still, and the spending has to keep rising for revenue to keep rising. Read it beside the growth rate, not alone.

  • Is the buyback buying ownership, or mopping up? 4.4%
    Stock pay, share count unread
    Stock compensation $14M (fiscal 2025), 4.4% of revenue · no repurchases · the share count is not comparable across these years (a split or a first listing sits in the record), so the drift is withheld
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $312M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 2.11×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $6M vs $193M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 9 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.49/share (latest year $2.09), the averaged base the calculator's gate runs on, and book value is $5.20/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2015–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 1 of 10
    What this means

    Lost money in 9 year(s), look at what happened there before trusting the average.

  • Operating margin −9657% → −15608% (3-yr avg ends)

    In the filing’s words The filing attributes gains to higher prices, but the margin in the record has not followed — the claim outruns the result here.

    What this means

    The recent-years average (−15608%) sits below the early years (−9657%), but the latest year (48%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is −9997% — read it across the cycle, not on the dip.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2022 · −46819.9% op. margin
    What this means

    Operations went underwater in 2022, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$481M
  • Cash & short-term investments$257M
  • Receivables$161M
  • Inventory$39M
  • Other current assets$24M
Current liabilities$187M
  • Accounts payable$10M
  • Other current liabilities$177M
Current ratio2.56×all current assets ÷ what's due · Graham looked for 2×
Quick ratio2.36×stricter: inventory excluded
Cash ratio1.37×strictest: cash alone against what's due
Working capital$293Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+156.5%the freshest read on whether the business is still growing
Current ratio, recent quarters4.0× → 2.6×
Deeper floors
Tangible book value$72Mequity stripped of goodwill & intangibles
Net current asset value$37MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$3M$3M of it operating leases

From the company's latest filing.

Acquisitions & goodwill

from the balance sheet & the 10-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$409M50% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equity7%goodwill is this share of book equity; the rest is the company’s own retained and paid-in capital
Cash spent acquiring$309Mover 1 years since fiscal 2025 buying other businesses, against $4M of capital spent building over the 10-year record

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Beside that spending sits $14M of cumulative amortization of acquired intangibles charged against earnings since fiscal 2024 — the purchase price of past deals, expensed over time.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and amortization summed across the company's full tagged history, write-downs across the 10-year record, from the company's own filings.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearPay, as filed“Actually paid”Net income
2023$2.5M$1.9M
2024$2.4M$5.4M($18M)
2025$6.1M$8.9M$163M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Net income is the whole business's, as filed, for the same fiscal years.

  • Insider ownership3.5%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$14M

    The slice of the business handed to employees in shares in fiscal 2025, 4.4% of revenue, equal to 9.2% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Income taxes, Acquisitions, Contingencies as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
PHARPharming Group N.V.$376M89%6.9%-3%3y14%
MNKDMannKind Corporation$349M72%-62.3%-45%
CRMDCorMedix Inc.$312M-12%-1.6%2y-202%-30%2y
EOLSEvolus Inc.$297M68%-44.0%-142%-34%
IRWDIronwood Pharmaceuticals Inc.$296M94%3y27.3%44%35%
HROWHarrow Inc.$272M70%0.8%-11%4y-1%
LGNDLigand Pharmaceuticals$268M96%3y31.6%2%45%
ARVNArvinas Inc.$263M-305.8%-37%-105%
Group median72%-0.4%-11%-16%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what CorMedix Inc. has delivered.

$
Base

The assumptions

9.0% = the 4.65% 10-year Treasury (Aug 19, 2026) + 4.35 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’22–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.65%, as of Aug 19, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $250M on 78M shares outstanding, per the 10-Q cover, as of 2026-08-10; net cash $257M. The if-converted diluted count is 93M, 19% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($4M) runs well above depreciation (—), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $253M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "CorMedix Inc. (CRMD), the owner's record," https://ownerscorecard.com/c/CRMD, data as of 2026-08-17.

Manual order: ← CRM its page in the Manual CRNC →

Industry order: ← CPRX the Pharmaceuticals chapter CRNX →